Great Chesterford, United Kingdom

Jens Fullgrabe

This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignees: Biomodal Limited, Cambridge Epigenetix Limited. Active years: 2023-2026.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Jens Fullgrabe: Innovator in Nucleic Acid Analysis

Introduction

Jens Fullgrabe is a notable inventor based in Great Chesterford, GB. He has made significant contributions to the field of nucleic acid analysis, particularly through his innovative methods and systems. His work is essential for advancing genetic research and diagnostics.

Latest Patents

Jens Fullgrabe holds a patent for "Methods for analyzing nucleic acids." This patent provides methods, systems, and compositions for determining a base in a polynucleotide. The techniques he developed are particularly useful for performing 4-base, 5-base, or 6-base sequencing of polynucleotide molecules. This is especially relevant for analyzing samples from liquid biopsies or identifying low-frequency mutations.

Career Highlights

Fullgrabe is associated with Cambridge Epigenetix Limited, a company that focuses on innovative solutions in epigenetics. His work at the company has positioned him as a key player in the development of advanced sequencing technologies.

Collaborations

Jens Fullgrabe has collaborated with esteemed colleagues such as Shankar Balasubramanian and Walraj Singh Gosal. These partnerships have further enhanced the impact of his research and innovations in the field.

Conclusion

Jens Fullgrabe's contributions to nucleic acid analysis through his patented methods are paving the way for advancements in genetic research and diagnostics. His work continues to influence the scientific community and improve methodologies in the field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…